HUP0203162A3
(en)
*
|
1999-08-12 |
2006-07-28 |
Wyeth Holdings Corp Madison |
Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer
|
US6432979B1
(en)
|
1999-08-12 |
2002-08-13 |
American Cyanamid Company |
Method of treating or inhibiting colonic polyps and colorectal cancer
|
US6924285B2
(en)
|
2002-03-30 |
2005-08-02 |
Boehringer Ingelheim Pharma Gmbh & Co. |
Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
|
GB0309850D0
(en)
|
2003-04-30 |
2003-06-04 |
Astrazeneca Ab |
Quinazoline derivatives
|
EP2348110B1
(en)
|
2003-05-30 |
2013-03-27 |
OncoTherapy Science, Inc. |
Process for screening a drug response in cancer patients
|
GB0326459D0
(en)
|
2003-11-13 |
2003-12-17 |
Astrazeneca Ab |
Quinazoline derivatives
|
PT1746999E
(en)
|
2004-05-06 |
2012-01-11 |
Warner Lambert Co |
4-phenylamino-quinazolin-6-yl-amides
|
JP4881875B2
(en)
|
2004-12-14 |
2012-02-22 |
アストラゼネカ アクチボラグ |
Pyrazolopyrimidine compounds as antitumor agents
|
WO2006071079A1
(en)
*
|
2004-12-29 |
2006-07-06 |
Hanmi Pharm. Co., Ltd. |
Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof
|
WO2007034144A1
(en)
|
2005-09-20 |
2007-03-29 |
Astrazeneca Ab |
4- (ih-indazol-s-yl-amino)-quinazoline compounds as erbb receptor tyrosine kinase inhibitors for the treatment of cancer
|
EP2386655B1
(en)
|
2006-09-12 |
2014-11-19 |
Genentech, Inc. |
Methods and compositions for the diagnosis and treatment of lung cancer using KIT or KDG gene as genetic marker
|
EP1921070A1
(en)
|
2006-11-10 |
2008-05-14 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Bicyclic heterocycles, medicaments comprising them, their use and process for their preparation
|
JP5377332B2
(en)
|
2007-02-06 |
2013-12-25 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Bicyclic heterocycles, drugs containing these compounds, their use and their preparation
|
US20110104166A1
(en)
|
2008-01-18 |
2011-05-05 |
Stankovic Konstantina M |
Methods and Compositions for Treating Polyps
|
TWI472339B
(en)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
|
EA019709B1
(en)
|
2008-02-07 |
2014-05-30 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Spirocyclic heterocycles and use thereof as medicaments
|
CA2723989C
(en)
|
2008-05-13 |
2017-04-25 |
Astrazeneca Ab |
Fumarate salt of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(n-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline
|
US8426430B2
(en)
*
|
2008-06-30 |
2013-04-23 |
Hutchison Medipharma Enterprises Limited |
Quinazoline derivatives
|
CA2733153C
(en)
|
2008-08-08 |
2016-11-08 |
Boehringer Ingelheim International Gmbh |
Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
|
MA33198B1
(en)
|
2009-03-20 |
2012-04-02 |
Genentech Inc |
ANTI-HER DI-SPECIFIC ANTIBODIES
|
EP2498817A2
(en)
|
2009-11-12 |
2012-09-19 |
F. Hoffmann-La Roche AG |
A method of promoting dendritic spine density
|
BR112012017269A2
(en)
|
2010-01-12 |
2016-05-03 |
Hoffmann La Roche |
tricyclic heterocyclic compounds, compositions and methods of use thereof
|
MX2012008958A
(en)
|
2010-02-18 |
2012-08-23 |
Genentech Inc |
Neuregulin antagonists and use thereof in treating cancer.
|
CN102869359A
(en)
|
2010-03-17 |
2013-01-09 |
弗·哈夫曼-拉罗切有限公司 |
Imidazopyridine compounds, compositions and methods of use
|
KR20130058672A
(en)
|
2010-04-16 |
2013-06-04 |
제넨테크, 인크. |
Foxo3a as predictive biomarker for pi3k/akt kinase pathway inhibitor efficacy
|
RU2013114360A
(en)
|
2010-08-31 |
2014-10-10 |
Дженентек, Инк. |
BIOMARKERS AND TREATMENT METHODS
|
US8697708B2
(en)
|
2010-09-15 |
2014-04-15 |
F. Hoffmann-La Roche Ag |
Azabenzothiazole compounds, compositions and methods of use
|
WO2012066061A1
(en)
|
2010-11-19 |
2012-05-24 |
F. Hoffmann-La Roche Ag |
Pyrazolopyridines and pyrazolopyridines and their use as tyk2 inhibitors
|
WO2012085176A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors
|
WO2013007768A1
(en)
|
2011-07-13 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
|
WO2013007765A1
(en)
|
2011-07-13 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Fused tricyclic compounds for use as inhibitors of janus kinases
|
CN103889976A
(en)
|
2011-08-12 |
2014-06-25 |
弗·哈夫曼-拉罗切有限公司 |
Indazole compounds, compositions and methods of use
|
MX2014001766A
(en)
|
2011-08-17 |
2014-05-01 |
Genentech Inc |
Neuregulin antibodies and uses thereof.
|
CN103827115A
(en)
|
2011-09-20 |
2014-05-28 |
弗·哈夫曼-拉罗切有限公司 |
Imidazopyridine compounds, compositions and methods of use
|
WO2013081645A2
(en)
|
2011-11-30 |
2013-06-06 |
Genentech, Inc. |
Erbb3 mutations in cancer
|
CN104220457A
(en)
|
2012-03-27 |
2014-12-17 |
霍夫曼-拉罗奇有限公司 |
Diagnosis and treatments relating to her3 inhibitors
|
JP2016509045A
(en)
|
2013-02-22 |
2016-03-24 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
How to treat cancer and prevent drug resistance
|
EP2964260A2
(en)
|
2013-03-06 |
2016-01-13 |
F. Hoffmann-La Roche AG |
Methods of treating and preventing cancer drug resistance
|
MX2015011898A
(en)
|
2013-03-13 |
2016-05-05 |
Genentech Inc |
Pyrazolo compounds and uses thereof.
|
JP2016515132A
(en)
|
2013-03-14 |
2016-05-26 |
ジェネンテック, インコーポレイテッド |
Combination and use of MEK inhibitor compounds with HER3 / EGFR inhibitor compounds
|
CA2905070A1
(en)
|
2013-03-14 |
2014-09-25 |
Genentech, Inc. |
Methods of treating cancer and preventing cancer drug resistance
|
JP2016520528A
(en)
|
2013-03-15 |
2016-07-14 |
ジェネンテック, インコーポレイテッド |
Cancer treatment and anticancer drug resistance prevention method
|
KR20160049003A
(en)
|
2013-09-05 |
2016-05-04 |
제넨테크, 인크. |
Antiproliferative compounds
|
AR097894A1
(en)
|
2013-10-03 |
2016-04-20 |
Hoffmann La Roche |
CDK8 THERAPEUTIC INHIBITORS OR USE OF THE SAME
|
KR20160070136A
(en)
|
2013-10-18 |
2016-06-17 |
제넨테크, 인크. |
Anti-rsp02 and/or anti-rsp03 antibodies and their uses
|
BR112016013963A2
(en)
|
2013-12-17 |
2017-10-10 |
Genentech Inc |
combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
EP3083686B2
(en)
|
2013-12-17 |
2023-03-22 |
F. Hoffmann-La Roche AG |
Methods of treating cancers using pd-1 axis binding antagonists and taxanes
|
CN107002119A
(en)
|
2014-03-24 |
2017-08-01 |
豪夫迈·罗氏有限公司 |
Treatment of cancer and the former and associating that HGF is expressed using C MET antagonists
|
PE20211291A1
(en)
|
2014-03-31 |
2021-07-20 |
Genentech Inc |
ANTI-OX40 ANTIBODIES AND METHODS OF USE
|
SG11201608106PA
(en)
|
2014-03-31 |
2016-10-28 |
Genentech Inc |
Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
|
WO2016036873A1
(en)
|
2014-09-05 |
2016-03-10 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
EP3193866A1
(en)
|
2014-09-19 |
2017-07-26 |
Genentech, Inc. |
Use of cbp/ep300 and bet inhibitors for treatment of cancer
|
WO2016057924A1
(en)
|
2014-10-10 |
2016-04-14 |
Genentech, Inc. |
Pyrrolidine amide compounds as histone demethylase inhibitors
|
RU2017119231A
(en)
|
2014-11-03 |
2018-12-06 |
Дженентек, Инк. |
METHODS AND BIOMARKERS FOR PREDICTING EFFICIENCY AND EVALUATING TREATMENT WITH OX40 AGONIST
|
RU2017119009A
(en)
|
2014-11-03 |
2018-12-05 |
Дженентек, Инк. |
ANALYSIS FOR DETECTION OF SUBPOPULATIONS OF IMMUNE T-CELLS AND WAYS OF THEIR APPLICATION
|
CN107073126A
(en)
|
2014-11-06 |
2017-08-18 |
豪夫迈·罗氏有限公司 |
Combination treatment comprising OX40 combinations activator and TIGIT inhibitor
|
MA40943A
(en)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
SUBSTITUTED PYRROLOPYRIDINES USED AS BROMODOMA INHIBITORS
|
CN107108613B
(en)
|
2014-11-10 |
2020-02-25 |
基因泰克公司 |
Bromodomain inhibitors and uses thereof
|
MA40940A
(en)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
SUBSTITUTED PYRROLOPYRIDINES USED AS BROMODOMA INHIBITORS
|
WO2016081384A1
(en)
|
2014-11-17 |
2016-05-26 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
WO2016086200A1
(en)
|
2014-11-27 |
2016-06-02 |
Genentech, Inc. |
4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors
|
CA2968359A1
(en)
|
2014-12-23 |
2016-06-30 |
Genentech, Inc. |
Compositions and methods for treating and diagnosing chemotherapy-resistant cancers
|
EP3240908A2
(en)
|
2014-12-30 |
2017-11-08 |
F. Hoffmann-La Roche AG |
Methods and compositions for prognosis and treatment of cancers
|
JP6889661B2
(en)
|
2015-01-09 |
2021-06-18 |
ジェネンテック, インコーポレイテッド |
4,5-Dihydroimidazole derivative and its use as a histone dimethylase (KDM2B) inhibitor
|
WO2016112298A1
(en)
|
2015-01-09 |
2016-07-14 |
Genentech, Inc. |
Pyridazinone derivatives and their use in the treatment of cancer
|
CN107406414B
(en)
|
2015-01-09 |
2022-04-19 |
基因泰克公司 |
(piperidin-3-yl) (naphthalen-2-yl) methanone derivatives as inhibitors of histone demethylase KDM2B for the treatment of cancer
|
JP6709792B2
(en)
|
2015-01-29 |
2020-06-17 |
ジェネンテック, インコーポレイテッド |
Therapeutic compounds and uses thereof
|
EP3250552B1
(en)
|
2015-01-30 |
2019-03-27 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
MA41598A
(en)
|
2015-02-25 |
2018-01-02 |
Constellation Pharmaceuticals Inc |
PYRIDAZINE THERAPEUTIC COMPOUNDS AND THEIR USES
|
KR20180002653A
(en)
|
2015-04-07 |
2018-01-08 |
제넨테크, 인크. |
Antigen binding complexes having an agonistic activity activity and methods of use
|
PT3294770T
(en)
|
2015-05-12 |
2020-12-04 |
Hoffmann La Roche |
Therapeutic and diagnostic methods for cancer
|
IL255372B
(en)
|
2015-05-29 |
2022-07-01 |
Genentech Inc |
Therapeutic and diagnostic methods for cancer
|
WO2016200836A1
(en)
|
2015-06-08 |
2016-12-15 |
Genentech, Inc. |
Methods of treating cancer using anti-ox40 antibodies
|
MX2017015937A
(en)
|
2015-06-08 |
2018-12-11 |
Genentech Inc |
Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists.
|
CA2986263A1
(en)
|
2015-06-17 |
2016-12-22 |
Genentech, Inc. |
Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
|
CA2996233C
(en)
|
2015-08-26 |
2024-01-16 |
Fundacion Del Sector Publico Estatal Centro Nacional De Investigaciones Oncologicas Carlos Iii (F.S.P. Cnio) |
Condensed tricyclic compounds as protein kinase inhibitors
|
RU2732591C2
(en)
|
2015-09-25 |
2020-09-21 |
Дженентек, Инк. |
Anti-tigit antibodies and methods of using
|
CA3008394A1
(en)
|
2015-12-16 |
2017-06-22 |
Genentech, Inc. |
Process for the preparation of tricyclic pi3k inhibitor compounds and methods of using the same for the treatment of cancer
|
CA3006529A1
(en)
|
2016-01-08 |
2017-07-13 |
F. Hoffmann-La Roche Ag |
Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
|
MX2018010361A
(en)
|
2016-02-29 |
2019-07-08 |
Genentech Inc |
Therapeutic and diagnostic methods for cancer.
|
WO2017180864A1
(en)
|
2016-04-14 |
2017-10-19 |
Genentech, Inc. |
Anti-rspo3 antibodies and methods of use
|
JP2019518426A
(en)
|
2016-04-15 |
2019-07-04 |
ジェネンテック, インコーポレイテッド |
Cancer diagnosis and treatment method
|
MX2018012492A
(en)
|
2016-04-15 |
2019-06-06 |
Genentech Inc |
Methods for monitoring and treating cancer.
|
CN109154027A
(en)
|
2016-04-15 |
2019-01-04 |
豪夫迈·罗氏有限公司 |
For monitoring and the method for the treatment of cancer
|
EP3464270B1
(en)
|
2016-05-24 |
2022-02-23 |
Genentech, Inc. |
Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
|
MA45146A
(en)
|
2016-05-24 |
2021-03-24 |
Constellation Pharmaceuticals Inc |
PYRAZOLOPYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER
|
CN109312407A
(en)
|
2016-06-08 |
2019-02-05 |
豪夫迈·罗氏有限公司 |
Diagnostic and therapeutic method for cancer
|
US11046776B2
(en)
|
2016-08-05 |
2021-06-29 |
Genentech, Inc. |
Multivalent and multiepitopic antibodies having agonistic activity and methods of use
|
CN109476748B
(en)
|
2016-08-08 |
2023-05-23 |
豪夫迈·罗氏有限公司 |
Methods for treatment and diagnosis of cancer
|
MX2019003934A
(en)
|
2016-10-06 |
2019-07-10 |
Genentech Inc |
Therapeutic and diagnostic methods for cancer.
|
CN110267678A
(en)
|
2016-10-29 |
2019-09-20 |
霍夫曼-拉罗奇有限公司 |
Anti- MIC antibody and application method
|
KR20190134631A
(en)
|
2017-03-01 |
2019-12-04 |
제넨테크, 인크. |
How to diagnose and treat cancer
|
CA3058279A1
(en)
|
2017-04-13 |
2018-10-18 |
F.Hoffmann-La Roche Ag |
An interleukin-2 immunoconjugate, a cd40 agonist, and optionally a pd-1 axis binding antagonist for use in methods of treating cancer
|
CA3073073A1
(en)
|
2017-09-08 |
2019-03-14 |
F. Hoffmann-La Roche Ag |
Diagnostic and therapeutic methods for cancer
|
WO2019090263A1
(en)
|
2017-11-06 |
2019-05-09 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
EP3797173A2
(en)
|
2018-05-21 |
2021-03-31 |
Nanostring Technologies, Inc. |
Molecular gene signatures and methods of using same
|
MX2020014091A
(en)
|
2018-06-23 |
2021-05-27 |
Genentech Inc |
Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor.
|
EP3823611A1
(en)
|
2018-07-18 |
2021-05-26 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
|
EP3847154A1
(en)
|
2018-09-03 |
2021-07-14 |
F. Hoffmann-La Roche AG |
Carboxamide and sulfonamide derivatives useful as tead modulators
|
WO2020061060A1
(en)
|
2018-09-19 |
2020-03-26 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
EP4249917A3
(en)
|
2018-09-21 |
2023-11-08 |
F. Hoffmann-La Roche AG |
Diagnostic methods for triple-negative breast cancer
|
CN113196061A
(en)
|
2018-10-18 |
2021-07-30 |
豪夫迈·罗氏有限公司 |
Methods of diagnosis and treatment of sarcoma-like renal cancer
|
WO2020163589A1
(en)
|
2019-02-08 |
2020-08-13 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
JP2022521773A
(en)
|
2019-02-27 |
2022-04-12 |
ジェネンテック, インコーポレイテッド |
Dosing for treatment with anti-TIGIT antibody and anti-CD20 antibody or anti-CD38 antibody
|
SG11202108707WA
(en)
|
2019-02-27 |
2021-09-29 |
Epiaxis Therapeutics Pty Ltd |
Methods and agents for assessing t-cell function and predicting response to therapy
|
WO2020223233A1
(en)
|
2019-04-30 |
2020-11-05 |
Genentech, Inc. |
Prognostic and therapeutic methods for colorectal cancer
|
EP3962947A2
(en)
|
2019-05-03 |
2022-03-09 |
F. Hoffmann-La Roche AG |
Methods of treating cancer with an anti-pd-l1 antibody
|
CN112300279A
(en)
|
2019-07-26 |
2021-02-02 |
上海复宏汉霖生物技术股份有限公司 |
Methods and compositions directed to anti-CD 73 antibodies and variants
|
JP2022547483A
(en)
|
2019-09-04 |
2022-11-14 |
ジェネンテック, インコーポレイテッド |
CD8 binding agents and uses thereof
|
CA3151406A1
(en)
|
2019-09-27 |
2021-04-01 |
Raymond D. Meng |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2021083949A1
(en)
|
2019-10-29 |
2021-05-06 |
F. Hoffmann-La Roche Ag |
Bifunctional compounds for the treatment of cancer
|
CA3155922A1
(en)
|
2019-11-06 |
2021-05-14 |
Huang Huang |
Diagnostic and therapeutic methods for treatment of hematologic cancers
|
CR20220207A
(en)
|
2019-11-13 |
2022-06-06 |
Genentech Inc |
Therapeutic compounds and methods of use
|
WO2021119505A1
(en)
|
2019-12-13 |
2021-06-17 |
Genentech, Inc. |
Anti-ly6g6d antibodies and methods of use
|
CA3164995A1
(en)
|
2019-12-20 |
2021-06-24 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
TW202142230A
(en)
|
2020-01-27 |
2021-11-16 |
美商建南德克公司 |
Methods for treatment of cancer with an anti-tigit antagonist antibody
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2021177980A1
(en)
|
2020-03-06 |
2021-09-10 |
Genentech, Inc. |
Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
|
EP4127724A1
(en)
|
2020-04-03 |
2023-02-08 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
JP2023523450A
(en)
|
2020-04-28 |
2023-06-05 |
ジェネンテック, インコーポレイテッド |
Methods and compositions for non-small cell lung cancer immunotherapy
|
WO2021257503A1
(en)
|
2020-06-16 |
2021-12-23 |
Genentech, Inc. |
Methods and compositions for treating triple-negative breast cancer
|
US20210395366A1
(en)
|
2020-06-18 |
2021-12-23 |
Genentech, Inc. |
Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
|
US11787775B2
(en)
|
2020-07-24 |
2023-10-17 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
EP4189121A1
(en)
|
2020-08-03 |
2023-06-07 |
Genentech, Inc. |
Diagnostic and therapeutic methods for lymphoma
|
EP4196612A1
(en)
|
2020-08-12 |
2023-06-21 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
JP2023544450A
(en)
|
2020-09-23 |
2023-10-23 |
エラスカ・インコーポレイテッド |
Tricyclic pyridones and pyrimidone
|
CA3193952A1
(en)
|
2020-10-05 |
2022-04-14 |
Bernard Martin Fine |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
US20230107642A1
(en)
|
2020-12-18 |
2023-04-06 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
EP4291558A1
(en)
|
2021-02-12 |
2023-12-20 |
F. Hoffmann-La Roche AG |
Bicyclic tetrahydroazepine derivatives for the treatment of cancer
|
CA3221390A1
(en)
|
2021-05-25 |
2022-12-01 |
Erasca, Inc. |
Sulfur-containing heteroaromatic tricyclic kras inhibitors
|
WO2022266206A1
(en)
|
2021-06-16 |
2022-12-22 |
Erasca, Inc. |
Kras inhibitor conjugates
|
TW202321261A
(en)
|
2021-08-10 |
2023-06-01 |
美商伊瑞斯卡公司 |
Selective kras inhibitors
|
TW202340212A
(en)
|
2021-11-24 |
2023-10-16 |
美商建南德克公司 |
Therapeutic compounds and methods of use
|
TW202332429A
(en)
|
2021-11-24 |
2023-08-16 |
美商建南德克公司 |
Therapeutic compounds and methods of use
|
WO2023191816A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023219613A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
WO2024015897A1
(en)
|
2022-07-13 |
2024-01-18 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024020432A1
(en)
|
2022-07-19 |
2024-01-25 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024033457A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024033388A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024033389A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024033458A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydroazepine derivatives
|
WO2024085242A2
(en)
|
2022-10-21 |
2024-04-25 |
Kawasaki Institute Of Industrial Promotion |
Non-fouling or super stealth vesicle
|
WO2024091991A1
(en)
|
2022-10-25 |
2024-05-02 |
Genentech, Inc. |
Therapeutic and diagnostic methods for multiple myeloma
|